Companies To Watch
The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.
Companies To Watch: Imago BioSciences
In developing a new drug for MPN diseases, Imago is entering a space where two potential competitors, Jakafi and Inrebic, both JAK (janus associated kinase) inhibitors, are already on the market.
Companies To Watch: Scynexis
Scynexis is creating multiple development programs and a new class of antifungals — all in a single, and singular, drug.
Companies To Watch: Obsidian Therapeutics
Obsidian Therapeutics targets gene and cell therapies with a technology designed to control the production and activity of therapeutic proteins those therapies induce.
Companies To Watch: eXIthera
This month’s company to watch is eXIthera, which is focused on inhibiting Factor XIa, a new target that may offer a way to avoid the bleeding problems with current anticoagulants.
Companies To Watch: Leading Biosciences
Leading Biosciences is applying the science of digestive proteases to treating or preventing multiple diseases and conditions, starting with delayed return of post-surgical bowel function (ileus) and adhesion with its lead product candidate, coded LB1148.
Companies To Watch: Bioharmony Therapeutics
Bioharmony Therapeutics is developing novel, “lysin-based” antimicrobials. The company is out to change the world of antibiotics, not by tweaking an old formula, but by advancing an entirely new mode of action.
Companies To Watch: Angion
Angion is developing a small molecule mimetic of the hepatocyte growth factor (HGF), which works to protect kidney and other organ cells from damage due to disease, physical injury, and indirect consequences of surgery and trauma.
Companies To Watch: Synlogic
Synlogic is an early-stage developer of “synthetic biotic” medicines — therapeutics consisting of beneficial microbes genetically engineered to treat rare metabolic diseases.
Companies To Watch: Provention Bio
This 15-person virtual biotech is trying to stop immune-mediated disease early, before it becomes a chronic condition.
Companies To Watch: Vyome Therapeutics
Vyome Therapeutics has built platforms and is developing products that address antibiotic resistance in severe skin conditions.
Companies To Watch: Azitra
Azitra is a small, young, early-stage company developing microbial biotherapeutics for conditions arising on the skin that can be addressed by using the microbiome.
Companies-To-Watch 2018 Annual Roundup
At the end of every year since we began the monthly column, Companies to Watch, I have gone back to the featured companies and asked each one to send me a short assessment of its progress since it appeared in Life Science Leader.
Companies to Watch —Where Are They Now?
Since launching our Companies To Watch section in 2012 we have covered more than 50 companies. This year we plan to periodically look back at some of them and see where they are today.
Companies To Watch: Synspira
Synspira is developing glycopolymer drugs for infection, inflammation, and congestion in the lungs. According CEO Shenda Baker, “We would like to see more companies in this space. But we are also looking forward to leading the way.”
BEYOND THE PRINTED PAGE
Food For Free – An Example Of How Life Science Cares Approaches Engagement
Food For Free is an example for how Life Science Cares engages with its community of greater Boston.
An Interview with Robert Hariri, M.D., Ph.D., CEO and founder of Celularity
A video of Life Science Leader chief editor, Rob Wright, interviewing Robert (Bob) Hariri, M.D., Ph.D., CEO and founder of Celularity, at the 2019 CNS Summit.
Why Top Researchers And Physicians Enter The World Of Biopharma R&D
David Chang, M.D., Ph.D., founder and CEO of Allogene Therapeutics, along with numerous other physicians have opted to become biopharmaceutical executives, but one doesn’t have to go to medical school to be driven to make a difference for patients.
LIFE SCIENCE LEADER BLOGS
BIO CEO 2020 Is No JPM — And That’s A Good Thing
Chief editor Rob Wright provides an overview of some of his experiences from recent attendance at the BIO CEO and Investor Conference in New York.
JPM Welcomes Life Sciences Into What Could Be The Roaring Twenties Of Discovery
Rob Wright shares his thoughts on the 38th Annual J.P. Morgan Healthcare Conference and “JPM” as we enter a decade that could be “roaring with cures.” Content specifically curated for professional development of c-level life science leaders.